JP2021502122A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021502122A5 JP2021502122A5 JP2020544370A JP2020544370A JP2021502122A5 JP 2021502122 A5 JP2021502122 A5 JP 2021502122A5 JP 2020544370 A JP2020544370 A JP 2020544370A JP 2020544370 A JP2020544370 A JP 2020544370A JP 2021502122 A5 JP2021502122 A5 JP 2021502122A5
- Authority
- JP
- Japan
- Prior art keywords
- mhc
- cells
- genetically modified
- chimeric receptor
- immune cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024203947A JP2025019209A (ja) | 2017-11-10 | 2024-11-22 | 主要組織適合複合体ベースのキメラ受容体および自己免疫疾患を治療するためのその使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762584449P | 2017-11-10 | 2017-11-10 | |
| US62/584,449 | 2017-11-10 | ||
| PCT/US2018/060227 WO2019094847A1 (en) | 2017-11-10 | 2018-11-10 | Major histocompatibility complex-based chimeric receptors and uses thereof for treating autoimmune diseases |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024203947A Division JP2025019209A (ja) | 2017-11-10 | 2024-11-22 | 主要組織適合複合体ベースのキメラ受容体および自己免疫疾患を治療するためのその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021502122A JP2021502122A (ja) | 2021-01-28 |
| JP2021502122A5 true JP2021502122A5 (https=) | 2021-12-23 |
| JP7594439B2 JP7594439B2 (ja) | 2024-12-04 |
Family
ID=66438683
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020544370A Active JP7594439B2 (ja) | 2017-11-10 | 2018-11-10 | 主要組織適合複合体ベースのキメラ受容体および自己免疫疾患を治療するためのその使用 |
| JP2024203947A Pending JP2025019209A (ja) | 2017-11-10 | 2024-11-22 | 主要組織適合複合体ベースのキメラ受容体および自己免疫疾患を治療するためのその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024203947A Pending JP2025019209A (ja) | 2017-11-10 | 2024-11-22 | 主要組織適合複合体ベースのキメラ受容体および自己免疫疾患を治療するためのその使用 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US11826385B2 (https=) |
| EP (1) | EP3707247A4 (https=) |
| JP (2) | JP7594439B2 (https=) |
| KR (2) | KR20250067182A (https=) |
| CN (2) | CN111373031A (https=) |
| AU (2) | AU2018365080B2 (https=) |
| CA (1) | CA3081583A1 (https=) |
| IL (2) | IL310483B2 (https=) |
| SG (1) | SG11202004202QA (https=) |
| WO (1) | WO2019094847A1 (https=) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020081764A1 (en) * | 2018-10-18 | 2020-04-23 | Synerk Inc. | Compositions and methods for inhibiting tigit gene expression |
| JP2022533713A (ja) | 2019-05-21 | 2022-07-25 | サンガモ セラピューティクス， インコーポレイテッド | 調節性ｔ細胞における制御された導入遺伝子発現 |
| CN110257376A (zh) * | 2019-06-03 | 2019-09-20 | 上海长海医院 | 一种CRISPR/Cas9基因编辑方法敲除角质形成细胞中PD-L1基因的方法 |
| WO2021007580A1 (en) | 2019-07-11 | 2021-01-14 | Valkyr, Inc. | System and methods relating to chimeric autoantibody receptors |
| CN110872577B (zh) * | 2020-01-20 | 2020-05-08 | 中国科学院动物研究所 | 修饰的免疫细胞及其应用 |
| US20210268023A1 (en) * | 2020-03-01 | 2021-09-02 | The Trustees Of Columbia University In The City Of New York | Enhanced CAR Tregs and Bi-Specific Antibodies for Induction of Immune Tolerance, Treating Autoimmune Diseases and Preventing Transplantation Rejection |
| WO2022165419A1 (en) * | 2021-02-01 | 2022-08-04 | Kyverna Therapeutics, Inc. | Methods for increasing t-cell function |
| EP4039808A1 (en) * | 2021-02-08 | 2022-08-10 | Ospedale San Raffaele S.r.l. | Guide rnas and uses thereof |
| US12577290B2 (en) | 2021-03-04 | 2026-03-17 | Allogene Therapeutics, Inc. | FasL expression and FasR gene knockout to protect therapeutic cells from allogeneic rejection and activation-induced cell death |
| CN117715929A (zh) * | 2021-07-29 | 2024-03-15 | 南特细胞公司 | 用于预防和治疗病毒感染和癌症的经修饰的t细胞受体 |
| US20240360198A1 (en) * | 2021-09-01 | 2024-10-31 | National University Corporation Kanazawa University | Immunoregulatory method, nucleic acid composition for immunoregulation, and use thereof |
| EP4453021A4 (en) * | 2021-12-22 | 2025-12-31 | Memorial Sloan Kettering Cancer Center | CELLS EXPRESSING FAS LIGAND POLYPEPTIDES AND FAS INACTIVATION AND THEIR USES |
| US20250304913A1 (en) * | 2022-04-06 | 2025-10-02 | The Regents Of The University Of Colorado, A Body Corporate | Chimeric antigen receptor t cells and methods of use thereof |
| WO2023235856A1 (en) * | 2022-06-03 | 2023-12-07 | Jura Bio, Inc | Apoptosis resistant immune cells with major histocompatibility complex chimeric antigen receptor |
| CN116284447A (zh) * | 2023-02-20 | 2023-06-23 | 苏州大学 | 一种靶向pd1嵌合抗原受体修饰的调节性t细胞及其制备方法与应用 |
| NL2037452B1 (en) * | 2024-04-12 | 2025-11-03 | Academisch Ziekenhuis Leiden | Agents for treating Celiac Disease |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL151860A0 (en) * | 2000-03-27 | 2003-04-10 | Technion Res & Dev Foundation | Single chain class i major histocompatibility complexes, constructs encoding same and methods of generating same |
| IL136511A0 (en) * | 2000-06-01 | 2001-06-14 | Gavish Galilee Bio Appl Ltd | Genetically engineered mhc molecules |
| ATE509025T1 (de) * | 2002-06-12 | 2011-05-15 | Gavish Galilee Bio Appl Ltd | ßMIT MHC-KLASSE-I-PEPTIDEPITOPEN KOVALENT VERKN PFTES MEMBRANVERANKERTES BETA2-MIKROGLOBULINß |
| US20080286312A1 (en) * | 2002-06-12 | 2008-11-20 | Gavish-Galilee Bio Applications Ltd. | Membrane-anchored beta2 microglobulincovalently linked to MHC class I peptide epitopes |
| EP2331566B1 (en) * | 2008-08-26 | 2015-10-07 | City of Hope | Method and compositions for enhanced anti-tumor effector functioning of t cells |
| EP2632955A1 (en) * | 2010-10-26 | 2013-09-04 | Technion Research & Development Foundation Ltd. | Antibodies which bind soluble t-cell receptor ligands |
| EP3013361B1 (en) | 2013-06-24 | 2021-10-06 | NexImmune, Inc. | Compositions and methods for immunotherapy |
| US10144770B2 (en) | 2013-10-17 | 2018-12-04 | National University Of Singapore | Chimeric receptors and uses thereof in immune therapy |
| WO2015179801A1 (en) | 2014-05-23 | 2015-11-26 | University Of Florida Research Foundation, Inc. | Car based immunotherapy |
| TWI751102B (zh) * | 2014-08-28 | 2022-01-01 | 美商奇諾治療有限公司 | 對ｃｄ１９具專一性之抗體及嵌合抗原受體 |
| EP2990416B1 (en) | 2014-08-29 | 2018-06-20 | GEMoaB Monoclonals GmbH | Universal chimeric antigen receptor expressing immune cells for targeting of diverse multiple antigens and method of manufacturing the same and use of the same for treatment of cancer, infections and autoimmune disorders |
| CA2972714A1 (en) * | 2014-09-09 | 2016-03-17 | Unum Therapeutics | Chimeric receptors and uses thereof in immune therapy |
| EP3569244A1 (en) * | 2015-09-23 | 2019-11-20 | CytoImmune Therapeutics, LLC | Flt3 directed car cells for immunotherapy |
-
2018
- 2018-11-10 KR KR1020257013703A patent/KR20250067182A/ko active Pending
- 2018-11-10 EP EP18875538.3A patent/EP3707247A4/en active Pending
- 2018-11-10 WO PCT/US2018/060227 patent/WO2019094847A1/en not_active Ceased
- 2018-11-10 AU AU2018365080A patent/AU2018365080B2/en active Active
- 2018-11-10 KR KR1020207014659A patent/KR102802061B1/ko active Active
- 2018-11-10 CA CA3081583A patent/CA3081583A1/en active Pending
- 2018-11-10 CN CN201880074245.5A patent/CN111373031A/zh active Pending
- 2018-11-10 US US16/762,723 patent/US11826385B2/en active Active
- 2018-11-10 IL IL310483A patent/IL310483B2/en unknown
- 2018-11-10 IL IL274239A patent/IL274239B2/en unknown
- 2018-11-10 SG SG11202004202QA patent/SG11202004202QA/en unknown
- 2018-11-10 JP JP2020544370A patent/JP7594439B2/ja active Active
- 2018-11-10 CN CN202410673792.2A patent/CN118530373A/zh active Pending
-
2023
- 2023-10-19 US US18/490,445 patent/US12421293B2/en active Active
-
2024
- 2024-11-22 JP JP2024203947A patent/JP2025019209A/ja active Pending
-
2025
- 2025-10-17 AU AU2025252604A patent/AU2025252604A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021502122A5 (https=) | ||
| IL274239B2 (en) | Major histocompatibility complex-based chimeric receptors and uses thereof for treating autoimmune diseases | |
| Haabeth et al. | How do CD4+ T cells detect and eliminate tumor cells that either lack or express MHC class II molecules? | |
| KR101471647B1 (ko) | 변이 ｃｔｌａ4 유전자 이입 ｔ 세포 및 이를 포함하는 항암 면역치료용 조성물 | |
| JP7450892B2 (ja) | Ｎｋ細胞のための人工ｈｌａ陽性フィーダー細胞株及びその使用 | |
| JP6422134B2 (ja) | キメラ抗原受容体 | |
| US11299552B2 (en) | Eliminating MHC restriction from the T cell receptor as a strategy for immunotherapy | |
| JP2020062054A (ja) | ＭｙＤ８８およびＣＤ４０ポリペプチドによるキメラ抗原受容体の共刺激 | |
| JP2025078698A (ja) | 操作されたｔ細胞 | |
| CN113293131A (zh) | 制备用于t细胞疗法的t细胞的方法 | |
| TWI875737B (zh) | Ｔ細胞受體及其使用方法 | |
| WO2022037562A1 (en) | Engineered immunoresponsive cells and uses thereof | |
| KR20210144737A (ko) | T 세포 수용체 및 이의 사용 방법 | |
| JP7727547B2 (ja) | Ｔ細胞受容体及びその使用方法 | |
| CN119053618A (zh) | 嵌合ilt受体组合物和方法 | |
| US20240350632A1 (en) | Engineered immune cells for treating disorders, compositions and methods thereof | |
| WO2023247727A2 (en) | Engineered human t cells comprising a switchable chimeric antigen cell surface receptor and methods for generating them | |
| US20230322899A1 (en) | Fusion protein enhancing cell therapy | |
| Sasaki et al. | Antitumor activity of chimeric immunoreceptor gene‐modified Tc1 and Th1 cells against autologous carcinoembryonic antigen‐expressing colon cancer cells | |
| CN118055770A (zh) | 用于过继免疫疗法的具有增强的功能的表达cd3的自然杀伤细胞 | |
| US20240307442A1 (en) | Modified Cell Targeting Tumor ECM and Cellular Therapy thereof | |
| CN121038798A (zh) | Cd4+细胞毒性t细胞及其使用方法 | |
| WO2025130895A1 (zh) | 一种免疫细胞的制备方法及其用途 | |
| CN121941503A (zh) | 嵌合ilt受体组合物和方法 | |
| CN120322451A (zh) | T细胞受体 |